Clinical Trials Browser

Phase 1/2 × OTHER × LY3022855 × Clear all

NCT03101254 2024-07-17

LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma

Phase 1/2 Completed

5 enrolled 10 charts

Melanoma